![Evaluating Treatment Options for High-Risk Renal Cell Cancer – Alliance for Clinical Trials in Oncology](https://oncodaily.com/pub/uploads/2025/02/F9srGL1Q_400x400.png)
Bradley McGregor/X
Feb 13, 2025, 17:39
Evaluating Treatment Options for High-Risk Renal Cell Cancer – Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology shared a post on X:
“New Trial Alert!
Bradley McGregor from Dana-Farber Cancer Institute leads the Alliance for Clinical Trials in Oncology A032201 (STRIKE) to compare the effect of adding tivozanib to standard therapy pembrolizumab vs pembrolizumab alone to treat patients with high-risk renal cell cancer.”
More posts featuring Alliance for Clinical Trials in Oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 13, 2025, 17:58
Feb 13, 2025, 17:28
Feb 13, 2025, 17:15
Feb 13, 2025, 17:00
Feb 13, 2025, 16:14
Feb 13, 2025, 14:53
Feb 13, 2025, 12:35
Feb 13, 2025, 12:24
Feb 13, 2025, 12:12